Images
La Vanguardia and La Sexta, among other media, have published an article on research headed by Antonio Zorzano, head of the Complex Metabolic Diseases and Mitochondria Lab at IRB Barcelona, which has identified a protein that protects against non-alcoholic fatty liver. “Mitofusin 2 emerges as a possible therapeutic target to combat fatty liver, a disease for which there is currently no treatment,” says the scientist.
The study has also been recommended by F1000 Prime.
Link to La Vanguardia
Link to La Sexta
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
